Disease Landscape and Forecast Insights

Clarivate Epidemiology’s coverage of ulcerative colitis (UC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…

Clarivate Epidemiology’s coverage of eosinophilic esophagitis (EoE) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States…

The Crohn’s disease (CD) therapy market will grow steadily over the next 10 years as a result of the increasing use of biologics and targeted oral therapies. The well-established TNF-α…

TNF-alpha inhibitors (e.g., Johnson & Johnson Innovative Medicine’s Remicade, AbbVie’s Humira) are entrenched in the U.S. ulcerative colitis (UC) therapy market. Alternative treatment options…

Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and topical steroids. Although these therapies can alleviate EoE symptoms, their remission…

Clarivate Epidemiology’s coverage of Crohn’s disease comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the total and diagnosed prevalence…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key rheumatoid arthritis patient populations, covering 171 countries and…

Clarivate Epidemiology’s coverage of Crohn’s disease (CD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of CD…

We expect the ulcerative colitis (UC) therapy market to grow steadily over the next decade, primarily driven by the increasing use of non-tumor necrosis factor (TNF) biologics (e.g., Takeda’s…

Crohn’s disease (CD) is a chronic inflammatory bowel disorder characterized by diarrhea, abdominal pain, and weight loss. Tumor necrosis factor (TNF)-α inhibitors (e.g., Johnson & Johnson…

TNF-alpha inhibitors (Johnson & Johnson Innovative Medicine ’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s Entyvio), a JAK inhibitor (Pfizer’s Xeljanz), and an IL-12/23 inhibitor…

Opioid-induced constipation (OIC) is a condition in which bowel movements are infrequent or incomplete as a result of opioid medications. The treatment of OIC relies on various prescription…